Semi-Annual Consolidated Statement Of Cash Flows

SymBio Pharmaceuticals Limited - Filing #7272884

Concept 2024-01-01 to
2024-12-31
As at
2024-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
Semi-annual consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Subtotal
-3,476,377,000 JPY
171,781,000 JPY
Interest and dividends received
43,814,000 JPY
274,000 JPY
Net cash provided by (used in) operating activities
-3,416,518,000 JPY
-194,685,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-19,816,000 JPY
-204,250,000 JPY
Net cash provided by (used in) investing activities
-3,955,000 JPY
-376,696,000 JPY
Cash flows from financing activities
Proceeds from issuance of shares
728,850,000 JPY
692,400,000 JPY
Purchase of treasury shares
-768,000 JPY
-996,000 JPY
Net cash provided by (used in) financing activities
708,472,000 JPY
680,160,000 JPY
Effect of exchange rate change on cash and cash equivalents
158,574,000 JPY
125,673,000 JPY
Net increase (decrease) in cash and cash equivalents
-2,553,426,000 JPY
234,452,000 JPY
Cash and cash equivalents
3,963,580,000 JPY
6,517,007,000 JPY
6,282,554,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.